Skip to content

Inhibikase Therapeutics, Inc.: 10-Q filed 2026-08-11

What Inhibikase Therapeutics, Inc. reported in its quarterly report filed 2026-08-11 (fiscal Q2 2026): 32 published measures, 93 facts as tagged in accession 0001193125-26-344707.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-11
Fiscal period
fiscal Q2 2026
Accession
0001193125-26-344707 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Inhibikase Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-30163,588,612USD
At 2025-12-31181,204,516USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-06-3010,260,026USD
At 2025-12-318,300,837USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-30153,328,586USD
At 2026-03-31167,620,268USD
At 2025-12-31172,903,679USD
At 2025-06-3080,053,685USD
At 2025-03-3185,730,672USD
At 2024-12-3194,866,280USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-19,591,231USD91
2026-01-01 to 2026-06-30-35,972,071USD181
2026-01-01 to 2026-03-31-16,380,840USD90
2025-04-01 to 2025-06-30-9,915,523USD91
2025-01-01 to 2025-06-30-23,594,258USD181
2025-01-01 to 2025-03-31-13,678,735USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-24,503,334USD181
2025-01-01 to 2025-06-30-9,677,761USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2026-01-01 to 2026-06-300USD181
2025-01-01 to 2025-06-3013,399USD181

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2026-04-01 to 2026-06-300USD91
2026-01-01 to 2026-06-300USD181
2025-04-01 to 2025-06-300USD91
2025-01-01 to 2025-06-300USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-06-302,883,122USD181
2025-01-01 to 2025-06-3031,771USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-86,393,289USD181
2025-01-01 to 2025-06-3030,898,080USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30-178,651,871USD
At 2025-12-31-142,679,800USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-04-01 to 2026-06-30174,571,543shares91
2026-01-01 to 2026-06-30173,445,493shares181
2025-04-01 to 2025-06-3090,009,625shares91
2025-01-01 to 2025-06-3089,774,703shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-04-01 to 2026-06-30174,571,543shares91
2026-01-01 to 2026-06-30173,445,493shares181
2025-04-01 to 2025-06-3090,009,625shares91
2025-01-01 to 2025-06-3089,774,703shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.11USD/shares91
2026-01-01 to 2026-06-30-0.21USD/shares181
2025-04-01 to 2025-06-30-0.11USD/shares91
2025-01-01 to 2025-06-30-0.26USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.11USD/shares91
2026-01-01 to 2026-06-30-0.21USD/shares181
2025-04-01 to 2025-06-30-0.11USD/shares91
2025-01-01 to 2025-06-30-0.26USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2026-04-01 to 2026-06-300USD91
2026-01-01 to 2026-06-300USD181
2025-04-01 to 2025-06-300USD91
2025-01-01 to 2025-06-300USD181

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-01-01 to 2026-06-3010,905,776USD181
2025-01-01 to 2025-06-306,250,938USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-21,050,995USD91
2026-01-01 to 2026-06-30-38,892,914USD181
2025-04-01 to 2025-06-30-10,832,278USD91
2025-01-01 to 2025-06-30-25,430,284USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-30162,343,915USD
At 2025-12-31180,109,395USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-06-3010,260,026USD
At 2025-12-318,300,837USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2026-06-30991,720USD
At 2025-12-311,158,054USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2026-04-01 to 2026-06-307,657,531USD91
2026-01-01 to 2026-06-3015,033,654USD181
2025-04-01 to 2025-06-305,919,731USD91
2025-01-01 to 2025-06-3011,169,022USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-04-01 to 2026-06-3013,393,464USD91
2026-01-01 to 2026-06-3024,232,614USD181
2025-04-01 to 2025-06-305,270,967USD91
2025-01-01 to 2025-06-3015,784,546USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-06-30132,032,636shares
At 2025-12-31131,691,237shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2026-06-3031,206,707USD
At 2025-12-31139,220,208USD
At 2025-06-3077,742,669USD
At 2024-12-3156,490,579USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2026-06-30-72,754USD
At 2025-12-3121,802USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2026-06-30244,697USD
At 2025-12-3195,121USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2026-06-30400,000USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2026-06-309,268,306USD
At 2025-12-314,081,282USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2026-06-30933,938USD
At 2025-12-31343,374USD

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2026-04-01 to 2026-06-300USD91
2026-01-01 to 2026-06-300USD181
2025-04-01 to 2025-06-3024,157USD91
2025-01-01 to 2025-06-3036,812USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2026-01-01 to 2026-06-302,897,611USD181
2025-01-01 to 2025-06-30150USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-196,334USD181
2025-01-01 to 2025-06-301,592,656USD181

Inspect the source

Entity
Inhibikase Therapeutics, Inc. / CIK 0001750149
Captured
2026-09-21T17:25:56.509Z
SEC response SHA-256
203698bfa89561c7804b33011fdebdf3b28ff82ca1d2a96ec2c0a9014e52024e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001750149.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))